Expert Analysis Reveals Critical Insights for Optimizing Care in LA-NSCLC
April 11th 2024Authors conducted a systematic literature review to gather evidence on the appropriateness of recommended treatments for locally advanced non–small cell lung cancer (LA-NSCLC) from the American Radium Society Appropriate Use Criteria Thoracic Committee.
Read More
Neoadjuvant Chemoimmunotherapy Shows Superiority in Non–Small Cell Lung Cancer Treatment
April 9th 2024The study compared the adverse events and surgical, pathological, and efficacy outcomes associated with neoadjuvant chemoimmunotherapy vs chemotherapy, particularly focusing on patients with PD-L1 levels less than 1%.
Read More
Navigating Complexity: Understanding Variations in Lung Cancer Screening Decision-Making
April 2nd 2024This analysis found the complex decision-making process of lung cancer screening among eligible individuals is infused with 3 principal themes that may influence how primary care physicians approach patients with comorbidities.
Read More
Wearable Activity Tracker Data Enhance Patient Assessment in Lung Cancer
March 28th 2024This analysis included 119 patients with advanced lung cancer, who were evaluated on 3 facets of physical activity over 14 days of using the amuelink wearable device from Sony: metabolic equivalent tasks, distance walked, and steps taken.
Read More
Low Screening Rates for Lung Cancer Highlight Public Health Priority
March 21st 2024Overall rates for lung cancer screening remain low, despite the US Preventive Services Task Force revising its annual screening recommendation in 2021 by lowering the age of initial screening for current or former smokers and their pack-year history.
Read More
ctDNA Holds Potential to Guide Management of EGFR-Mutated NSCLC
March 15th 2024A review explores the evidence supporting the use of circulating tumor DNA (ctDNA) liquid biopsies to help direct the evaluation and management of EGFR-mutated non–small cell lung cancer (NSCLC), including for assessing resistance to certain treatment options.
Read More
SABR Likely Safe, Effective for Patients Who Have NSCLC, ILD
March 12th 2024In this study, the 42-patient population was enrolled from 5 sites in Canada and 1 site in Scotland, and data were gathered from March 7, 2019, to January 12, 2022; all had interstitial lung disease (ILD) and early-stage non–small cell lung cancer (NSCLC).
Read More
Nivolumab Continues to Produce Beneficial NSCLC Outcomes
February 27th 2024This most recent analysis from the CheckMate 9LA trial provides 4-year follow-up data on patients with stage IV metastatic/recurrent non–small cell lung cancer (NSCLC) randomized to treatment with nivolumab plus ipilimumab and chemotherapy vs chemotherapy alone.
Read More
FDA Accepts BLA for Datopotamab Deruxtecan for Nonsquamous NSCLC
February 19th 2024The application is based on results of the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan in nonsquamous non–small cell lung cancer (NSCLC), first presented at the 2023 European Society for Medical Oncology Congress.
Read More
Durvalumab Consolidation Therapy Shows Promise in Elderly Patients With Stage III NSCLC
February 12th 2024Consolidation durvalumab led to comparable outcomes among older patients with unresectable stage III non–small cell lung cancer (NSCLC) vs a younger cohort with the same cancer; this patient population was underrepresented in the PACIFIC trial.
Read More
In-House Biomarker Testing Shortens Time to Treatment Decision for mNSCLC
February 9th 2024This retrospective analysis compared molecular testing outcomes among newly diagnosed cases of metastatic non–small cell lung cancer (mNSCLC) from 2 periods: March 2017 to May 2019 and July 2019 to March 2021.
Read More
Sacituzumab Govitecan Monotherapy for NSCLC Disappoints in EVOKE-01 Trial Update
January 23rd 2024The TROP-2–directed antibody drug conjugate is currently being investigated as a monotherapy and a combination therapy for non–small cell lung cancer (NSCLC) in 3 trials: phase 3 EVOKE-01, phase 2 EVOKE-02, and phase 3 EVOKE-03.
Read More
Molly Mendenhall on Standardizing Comprehensive Biomarker Testing in NSCLC
January 18th 2024Molly Mendenhall, BSN, RN, director of quality and compliance at Oncology Hematology Care, Inc (OHC), discussed a 1-year quality improvement project implemented by OHC to standardize comprehensive biomarker testing in patients with non–small cell lung cancer (NSCLC).
Read More
Hypofractionated Chemoradiation Regimen With an Adaptive SABR Boost Shows Promise in NSCLC
January 12th 2024An early-phase, dose-escalation study of a hypofractionated approach to concurrent chemoradiation using an an adaptive stereotactic ablative radiotherapy (SABR) boost showed promising results in patients with locally advanced, unresectable non–small cell lung cancer (NSCLC).
Read More
Updated Guidelines Expand Lung Cancer Screening Eligibility for At-Risk Patients: Dr Melinda Aldrich
January 5th 2024Melinda C. Aldrich, PhD, MPH, associate professor in the departments of medicine, thoracic surgery, and biomedical informatics at Vanderbilt University, discussed recently updated lung screening guidelines from the American Cancer Society and the importance of equity across populations as new guidelines are developed.
Read More
Frontline Serplulimab Plus Chemo Provides Consistent Survival Benefit in Squamous NSCLC
December 15th 2023The addition of serplulimab to carboplatin and nab-paclitaxel significantly prolonged survival vs chemotherapy alone when used in the first-line treatment of patients with previously untreated locally advanced or metastatic squamous non–small cell lung cancer.
Read More
Survival, PROs Favor Cemiplimab Plus Chemotherapy vs Chemotherapy Alone in Advanced NSCLC
December 4th 2023For patients with advanced non–small cell lung cancer (NSCLC), regardless of PD-L1 status, cemiplimab plus chemotherapy had favorable survival benefits and patient-reported outcomes over chemotherapy alone.
Read More
Perioperative Pembrolizumab Meets Dual Primary End Point of OS in NSCLC
October 14th 2023Pembrolizumab plus chemotherapy prior to surgery, followed by resection and single-agent pembrolizumab in the adjuvant setting, significantly improved overall survival (OS) vs neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in patients with resectable stage II, IIIA, or IIIB (T3-4N2) non–small cell lung cancer, meeting the dual primary end point of the phase 3 KEYNOTE-671 trial.
Read More